1-[(2E)-3-Phenylprop-2-enoyl]-1H-benzimidazoles as anticancer agents: synthesis, crystal structure analysis and binding studies of the most potent anticancer molecule with serum albumin. Issue 11 (23rd September 2015)

• Record Type: Journal Article
• Authors: Kalalbandi, Veerendra Kumar A.; Seetharamappa, J.
• Is Part Of: MedChemComm. Volume 6:Issue 11(2015:Nov.)
• Page Start: 1942
• Page End: 1953
• Publication Date: 2015-09-23
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19
• DOI: 10.1039/c5md00293a
• Languages: English
• ISSNs: 2040-2503

Abstract

Abstract : The anticancer activity of 1 H -benzimidazoles was studied against NCI 60 cell panel. Compound3f showed antitumor activity with good to moderate selectivity ratio. Mechanism of interaction of3f with protein was studied by spectral methods. Abstract : A series of 1-[(2 E )-3-phenylprop-2-enoyl]-1 H -benzimidazoles have been synthesized and their ability to inhibit the growth of cancer cell lines has been investigated against an NCI 60 cell panel. The compound 1-[(2 E )-3-phenylprop-2-enoyl]-2-(4-chlorophenyl)-1 H -benzimidazole (compound3f, NSC: 773404/1) was found to display good antitumor activity against the nine tumor subpanels with selectivity ratios ranging from 0.79 to 1.53 and from 0.47 to 1.69 at the GI50 and TGI levels, respectively. Structural parameters of the potent anticancer active compound, 3f, have been studied from single crystal XRD data. Further, the in vitro interactions of3f with the transport protein, human serum albumin (HSA), were investigated by spectroscopic techniques. A static quenching mechanism was seen in the binding of3f to HSA. Thermodynamic parameters revealed that hydrogen bonding and van der Waals forces played a major role in the interaction process.